The Gum Bacterium in 96% of Alzheimer's Brains | The Starved Brain, Chapter 8

Periodontal disease · dementia risk

Periodontal Disease and Dementia: A Screening Workflow

The oral exposure tied to dementia risk is severe periodontitis, and it lives in a dental chart that most medical records never import. Closing that gap is a workflow decision before it is a research question.

The periodontal disease dementia literature has matured past the point where it can be dismissed, and not to the point where it supports an intervention claim. Dr. Padda’s companion video for the book, The Gum Bacterium in 96% of Alzheimer’s Brains, reviews the argument from The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, including a correction of a claim his own side repeats. For a practice, the usable output is narrower than the headline: which patients carry the exposure, what documentation connects it to the cognitive and metabolic workup, and what a finding changes. Measura [Cardiometabolic and Autonomic Health Analysis] performs no dental, salivary or microbial testing. Its role here is the metabolic, vascular and cognitive measurement in the same patient.

Is periodontal disease a risk factor for dementia?

Five syntheses from independent teams land in a narrow band. Nadim pooled cohorts at RR 1.18 (1.06–1.31). Larvin reported dementia RR 1.22 and cognitive decline RR 1.33. Dibello reproduced dementia RR 1.22 and ran depression as a negative control, which came back null at RR 1.07 (0.95–1.21). The 2025 umbrella review gives cohorts RR 1.26 (1.20–1.32), low to moderate certainty by GRADE. Measurement quality points the right way: self-reported periodontitis produced weaker estimates than clinically examined disease, the pattern expected from a real exposure measured imperfectly.

The clinically decisive finding is severity. Pooling 13 case-control and 11 cohort studies, severe periodontitis carried OR 2.85 (2.16–3.74), while less-than-moderate disease carried OR 0.94 (0.64–1.40). Screening should therefore ask for staging, not a yes or no. The largest single estimate, HR 1.79 in 56,018 Taiwanese adults from claims data, partly measures who seeks care: people who see a dentist also see physicians.

Can periodontal bacteria reach the brain? Mechanism, with provenance

Dominy and colleagues found arginine-gingipain B in 51 of 53 Alzheimer’s temporal cortex samples, and lysine-gingipain in 91%, with RgpB tracking tau at r = 0.674 and ubiquitin at 0.786. The control column is less often quoted: RgpB in 18 of 46 non-demented samples, Kgp in 52%, and the bacterial gene in five of six control brains by qPCR. Twelve of twenty-five authors were employees of the company developing the inhibitor, and independent replication of the brain immunohistochemistry has not appeared. Ilievski’s wild-type mouse study, 10 exposed and 10 controls over 22 weeks, showed that oral inoculation can produce hippocampal inflammation, Aβ1–42 and phospho-tau. It reported pathology, not cognition. And a prospective human serology study of 158 cognitively intact adults found baseline antibodies in future cases to Fusobacterium nucleatum and Prevotella intermedia, not P. gingivalis. A 2026 review still judges that confounding, reverse causation and dental-care access preclude causal inference.

Does targeting P. gingivalis slow Alzheimer’s? GAIN and the genetic nulls

GAIN randomized 643 patients with mild-to-moderate Alzheimer’s at 93 sites to two doses of atuzaginstat or placebo for 48 weeks and missed both co-primary endpoints, ADAS-Cog11 and ADCS-ADL. Liver enzymes above three times the upper limit of normal occurred in 2% on placebo, 7% at 40 mg and 15% at 80 mg; FDA holds followed and the program closed in August 2022. In the pre-specified subgroup of 242 with salivary P. gingivalis DNA, ADAS-Cog11 decline was 57% slower at the higher dose, with no functional effect. The successor enrolls only organism-positive patients and reports in 2029. Two Mendelian randomization studies are null or unstable: Sun found OR 1.10 on one instrument set and 0.97 on a second, and Hu found no causal relationship.

The exclusion that matters to a primary care or endocrine panel: GAIN excluded HbA1c above 8 and BMI of 38 or more. The insulin-resistant, centrally obese patient whose inflammatory burden is highest never entered the one randomized test. A 48-week trial in established dementia may also be testing a decades-long exposure at the wrong end. That is a criticism of the design, not evidence for the drug.

Which patients should be screened for periodontal disease, and what does a finding change?

Ask about periodontal status, and request staging, in patients undergoing cognitive assessment, in patients with diabetes or insulin resistance, and in older adults with known severe disease or heavy tooth loss. The CDC full-mouth survey of 10,683 dentate adults found periodontitis in 42% of those 30 to 79 and severe disease in 7.8%, and partial-mouth protocols can underestimate prevalence by more than 50%, so a full-mouth chart with periodontal inflamed surface area is the document worth requesting. The structural driver is that the dental and medical records sit in different buildings, maintained by different systems, and neither side is prompted to ask for the other’s chart (selection criteria).

A finding of severe periodontitis changes management in concrete ways. It supports referral for periodontal treatment on its own merits: across 30 studies with 2,443 analyzed participants with diabetes, subgingival instrumentation lowered HbA1c by 0.43% at three to four months, moderate certainty, though 33 of 35 studies carried high or unclear risk of bias. It changes lab timing: in 120 patients with severe periodontitis, intensive treatment lowered flow-mediated dilatation and raised CRP and IL-6 at 24 hours, then improved dilatation by 180 days, so an hs-CRP drawn the day after treatment reads the procedure. And it argues for a cognitive assessment baseline, repeatable on the same instrument, rather than waiting for a complaint.

Where Measura measurement fits

Measura cannot stage the gums or detect the organism. It measures the terrain around the exposure. Laboratory panels put HbA1c, fasting insulin and inflammatory markers next to the dental chart; the Puerto Rico cohort of 1,206 overweight adults found that progression of attachment loss, IRR 1.25, rather than baseline periodontitis, tracked incident dysglycemia, so trending both charts together is more informative than either snapshot. Arterial stiffness and endothelial function testing covers the vascular domain in which the Tonetti trial documented systemic effects, without claiming to replicate its method. Bioimpedance body composition characterizes the adiposity that excluded patients from GAIN. Pair the cognitive baseline with fall-risk work where the patient population overlaps (cognitive assessment and fall prevention).

Documentation and workflow

Add periodontal staging to the history captured at the annual wellness visit, with the date of the dental chart it came from (annual wellness visit integration). Build the request for the dental chart into standing orders for patients meeting criteria, so it happens without depending on memory at the point of care (standing orders that make screening reproducible). A patient version of this material is written separately (the patient article on gum disease and dementia), the referenced evidence sits in the book companion (Chapter 8 companion), and the preceding physician article covers the metabolic inflammation that this oral source adds to (metaflammation screening).

Frequently asked questions

Should periodontal status be part of a cognitive workup?

Yes, as history and staging rather than as a diagnostic claim. The association is modest overall and concentrated in severe disease, and treatment is indicated independently of any brain effect. Recording stage and chart date costs one question and one records request, and it keeps a treatable inflammatory source from being missed in patients already under cognitive evaluation. Structuring that evaluation is covered in interpreting the report.

Is salivary P. gingivalis testing ready for clinical use?

Not on current evidence. Salivary DNA defined a pre-specified subgroup inside a failed trial, and the successor trial using it as an entry criterion does not report until 2029. It is a research stratifier. Measura does not offer it or any microbial test. The practical signal available now is periodontal staging from a full-mouth dental examination. The measurement rationale Measura does support is laid out in clinical rationale.

Does vitamin D belong in this workup?

It belongs for reasons the mouse models cannot test. The vitamin D response element driving cathelicidin, LL-37, sits in a primate-specific genetic element absent in mice, rats and dogs, so every animal study here is blind to that limb. No source sets a 25-hydroxyvitamin D level for adequate LL-37 production, and no LL-37 assay is validated clinically. Order it as part of the metabolic panel, not as a periodontal marker. See specialty applications.

How should inflammatory markers be timed around periodontal therapy?

Avoid the first days after intensive treatment. In the randomized trial of 120 patients with severe periodontitis, CRP, IL-6 and von Willebrand factor rose at 24 hours while flow-mediated dilatation fell, and vascular function improved by 180 days. A baseline before treatment and a repeat months later is interpretable; a draw the morning after is not. Scheduling repeat measurement is addressed in chronic care and between-visit monitoring.

How do dental findings get into the medical record?

Usually they do not, which is the problem. Request the full-mouth periodontal chart with bleeding on probing and inflamed surface area, and file the staging and date in a discrete history field rather than a scanned attachment, so it can be retrieved beside HbA1c and cognitive scores at the next visit. Options for structured results are described in getting results into the record.

Which dental disease is linked to Alzheimer’s disease and dementia?

Periodontitis, and specifically severe periodontitis. Pooling 13 case-control and 11 cohort studies, severe disease carried OR 2.85 (2.16–3.74), while less-than-moderate disease carried OR 0.94 (0.64–1.40). Pooled cohort estimates across all severities run from RR 1.18 to 1.26. That gradient is why a periodontal history should record stage from a full-mouth chart rather than a yes or no answer.

Does periodontal disease cause dementia?

Causation is not established. Five independent syntheses agree on a modest association, and clinically examined disease gives stronger estimates than self-report. But GAIN missed both co-primary endpoints, two Mendelian randomization studies were null or unstable, and a 2026 review still judges that confounding, reverse causation and dental-care access preclude causal inference. Periodontal treatment is indicated on its own merits regardless.

How common is periodontitis in adults?

In the CDC full-mouth survey of 10,683 dentate adults aged 30 to 79, 42% had periodontitis and 7.8% had severe disease. Partial-mouth protocols can underestimate prevalence by more than 50%, so a partial exam in the chart can miss much of it. The document worth requesting is a full-mouth chart with periodontal inflamed surface area.

See how the Measura protocol fits your practice

Learn how cognitive, metabolic and vascular measurements can sit beside periodontal history in your screening workflow, standing orders and wellness visit documentation.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Qadir, B. H., Mahmood, M. K., Amin, Y. M. M., Kurda, H. A., Rasheed, T. A., Noori, A. H., Noori, Z. F., Abdulghafor, M. A., Fadhil, H. N. M., Fatih, M. T., Tardivo, D., Tassery, H., & Lan, R. (2025). Periodontitis and tooth loss are associated with higher risks of cognitive disorders: A systematic umbrella meta-analysis. Clinical and Experimental Dental Research, 11(6), Article e70240. https://doi.org/10.1002/cre2.70240
Kim, D.-H., & Han, G.-S. (2025). Periodontitis as a risk factor for dementia: A systematic review and meta-analysis. The Journal of Evidence-Based Dental Practice, 25(2), Article 102094. https://doi.org/10.1016/j.jebdp.2025.102094
Larvin, H., Gao, C., Kang, J., Aggarwal, V. R., Pavitt, S., & Wu, J. (2023). The impact of study factors in the association of periodontal disease and cognitive disorders: Systematic review and meta-analysis. Age and Ageing, 52(2), Article afad015. https://doi.org/10.1093/ageing/afad015
Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., Holsinger, L. J., Arastu-Kapur, S., Kaba, S., Lee, A., Ryder, M. I., Potempa, B., Mydel, P., Hellvard, A., Adamowicz, K., … Potempa, J. (2019). Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science Advances, 5(1), Article eaau3333. https://doi.org/10.1126/sciadv.aau3333
Sparks Stein, P., Steffen, M. J., Smith, C., Jicha, G., Ebersole, J. L., Abner, E., & Dawson, D. (2012). Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimer’s & Dementia, 8(3), 196–203. https://doi.org/10.1016/j.jalz.2011.04.006
Sun, Y.-Q., Richmond, R. C., Chen, Y., & Mai, X.-M. (2020). Mixed evidence for the relationship between periodontitis and Alzheimer’s disease: A bidirectional Mendelian randomization study. PLoS ONE, 15(1), Article e0228206. https://doi.org/10.1371/journal.pone.0228206
Eke, P. I., Thornton-Evans, G. O., Wei, L., Borgnakke, W. S., Dye, B. A., & Genco, R. J. (2018). Periodontitis in US adults: National Health and Nutrition Examination Survey 2009–2014. Journal of the American Dental Association, 149(7), 576–588.e6. https://doi.org/10.1016/j.adaj.2018.04.023
Simpson, T. C., Clarkson, J. E., Worthington, H. V., MacDonald, L., Weldon, J. C., Needleman, I., Iheozor-Ejiofor, Z., Wild, S. H., Qureshi, A., Walker, A., Patel, V. A., Boyers, D., & Twigg, J. (2022). Treatment of periodontitis for glycaemic control in people with diabetes mellitus. Cochrane Database of Systematic Reviews, 4(4), Article CD004714. https://doi.org/10.1002/14651858.CD004714.pub4
Tonetti, M. S., D’Aiuto, F., Nibali, L., Donald, A., Storry, C., Parkar, M., Suvan, J., Hingorani, A. D., Vallance, P., & Deanfield, J. (2007). Treatment of periodontitis and endothelial function. New England Journal of Medicine, 356(9), 911–920. https://doi.org/10.1056/NEJMoa063186
Joshipura, K. J., Muñoz-Torres, F. J., Dye, B. A., Leroux, B. G., Ramírez-Vick, M., & Pérez, C. M. (2018). Longitudinal association between periodontitis and development of diabetes. Diabetes Research and Clinical Practice, 141, 284–293. https://doi.org/10.1016/j.diabres.2018.04.028